Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, February 05, 2025. Let’s ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Monday, February 03, 2025. Let’s ...

Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...

H.C. Wainwright reaffirmed their positive stance on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and a price target of $18.00, representing significant upside potential from the current price ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...

Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on ...

A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...

For instance, in December 2020, Vanda Pharmaceutical announced that the United States FDA had approved its HETLIOZ liquid and capsule formulations for the diagnosis of adults and children with ...